Research location
Waratah
New South Wales, Australia
Advertisement
Research activity in Waratah
New South Wales, AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 115 trials and 115 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Waratah
115 linked trials · page 1 of 3A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319 · 2026-06-15 · 1 site observation
RECRUITING
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · 2026-06-11 · 1 site observation
RECRUITING
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNCT07262619 · 2026-01-20 · 1 site observation
RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation
RECRUITING
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsNCT07334119 · 2025-11-25 · 1 site observation
RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation
RECRUITING
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerNCT07140900 · 2025-10-07 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 1 site observation
RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06 · 1 site observation
RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsNCT06914128 · 2025-03-21 · 1 site observation
RECRUITING
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerNCT06756932 · 2025-02-04 · 1 site observation
RECRUITING
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerNCT06712355 · 2025-02-03 · 1 site observation
RECRUITING
Implementing Surgery School Prehabilitation Using TelehealthNCT06631872 · 2025-01-22 · 1 site observation
RECRUITING
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation
RECRUITING
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306 · 2024-10-07 · 1 site observation
RECRUITING
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation
RECRUITING
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356 · 2023-11-16 · 1 site observation
RECRUITING
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsNCT05914116 · 2023-08-17 · 1 site observation
RECRUITING
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsNCT04913285 · 2021-08-04 · 1 site observation
RECRUITING
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542 · 2020-06-01 · 1 site observation
RECRUITING
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)NCT06593522 · 2024-12-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · 2024-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 · 2023-11-22 · 1 site observation
COMPLETED
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566 · 2023-05-31 · 1 site observation
ACTIVE_NOT_RECRUITING
Tucatinib Together With Pembrolizumab and TrastuzumabNCT04789096 · 2023-03-07 · 1 site observation
TERMINATED
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)NCT05665595 · 2023-01-19 · 1 site observation
TERMINATED
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNCT05252390 · 2022-03-29 · 1 site observation
TERMINATED
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)NCT05224141 · 2022-03-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate CancerNCT04905069 · 2021-12-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsNCT05266105 · 2021-12-10 · 1 site observation
ACTIVE_NOT_RECRUITING
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMANCT04319783 · 2021-06-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerNCT04746924 · 2021-05-24 · 1 site observation
TERMINATED
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396 · 2021-05-18 · 1 site observation
COMPLETED
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)NCT04777409 · 2021-05-18 · 1 site observation
COMPLETED
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast CancerNCT04752332 · 2021-05-10 · 1 site observation
TERMINATED
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)NCT04700072 · 2021-05-03 · 1 site observation
COMPLETED
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)NCT04704219 · 2021-02-23 · 1 site observation
COMPLETED
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaNCT04334759 · 2021-02-18 · 1 site observation
COMPLETED
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety and Tolerability of EXN407NCT04565756 · 2020-11-05 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)NCT04546009 · 2020-10-09 · 1 site observation
ACTIVE_NOT_RECRUITING
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidNCT04468659 · 2020-07-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)NCT04305054 · 2020-07-01 · 1 site observation
COMPLETED
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)NCT04305041 · 2020-06-26 · 1 site observation
COMPLETED
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerNCT04194944 · 2020-02-17 · 1 site observation
ACTIVE_NOT_RECRUITING
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsNCT04154956 · 2020-02-06 · 1 site observation
TERMINATED
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerNCT04188548 · 2019-12-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04177108 · 2019-11-25 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)NCT03834493 · 2019-07-28 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.